GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.81% | -1.51% | 10.67% | 19.21% | 24.40% |
| Total Depreciation and Amortization | -18.50% | -39.47% | -53.74% | -63.73% | -68.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 490.30% | 1,746.88% | 273.98% | 1,837.65% | -41.81% |
| Change in Net Operating Assets | -36.75% | -28.94% | -9.83% | 212.58% | 376.20% |
| Cash from Operations | -10.29% | 10.32% | 24.84% | 38.37% | 48.84% |
| Capital Expenditure | -- | -8,540.00% | -360.00% | 64.06% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 620.91% | 1,681.29% | 1,020.00% | 59.08% | -161.52% |
| Cash from Investing | 465.97% | 1,361.88% | 1,061.96% | 76.64% | -171.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 62.14% | 59.39% | 56.68% | -14.00% | -307.16% |
| Issuance of Common Stock | 11.09% | -41.76% | -60.95% | -60.74% | -60.50% |
| Repurchase of Common Stock | -60.00% | 75.00% | -- | 96.62% | 95.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 467.06% | 1,682.54% | 516.90% | 21.65% | -170.04% |
| Cash from Financing | 502.27% | 31.68% | -28.94% | -67.69% | -92.02% |
| Foreign Exchange rate Adjustments | 56.38% | 79.16% | 101.64% | -20.64% | -537.62% |
| Miscellaneous Cash Flow Adjustments | -- | 0.00% | -90.91% | -100.00% | 100.00% |
| Net Change in Cash | 122.59% | 124.13% | -70.15% | -205.90% | -213.21% |